Showing results (1951-1960 of 2,088) with videos related to
Sort By:
Pageof 209
Blood Cancer Journal|July 16, 2021
Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphomaPatrizia Mondello, Angelo Fama, Melissa C Larson, et al.Cytokine|September 7, 2013
Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohortsHervé Ghesquières, Matthew J Maurer, Olivier Casasnovas, et al.Blood|December 3, 2014
BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphomaCristina Correia, Paula A Schneider, Haiming Dai, et al.American Journal of Hematology|June 4, 2026
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell LymphomaZhengming Chen, Danny Luan, Rasmus Rask Kragh Jørgensen, et al.British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.Journal of Hepatology|November 13, 2024
HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replicationTatjana Schwarz, Johannes Ptok, Maximilian Damagnez, et al.Cancers|July 14, 2023
Higher Plasma Creatinine Is Associated with an Increased Risk of Death in Patients with Non-Metastatic Rectal but Not Colon Cancer: Results from an International Cohort ConsortiumJennifer Ose, Biljana Gigic, Stefanie Brezina, et al.American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.British Journal of Haematology|February 5, 2020
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patientsLasse H Jakobsen, Fredrik Ellin, Knut B Smeland, et al.American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.Pageof 209